The company outlined three broad areas where it expects to improve its performance. First, of course, is cutting costs and allocating resources where potential paybacks are largest. Under this heading comes maintaining a “high level of cash returned to shareholders” in dividends and stock buybacks.
Second, Merck says it plans to sharpen its commercial focus and increase its geographic focus on 10 prioritized markets: the United States, Japan, France, Germany, Canada, the United Kingdom, China, Brazil, Russia and Korea.
Third, the company will prioritize its R&D efforts “to focus on [drug] candidates capable of providing unambiguous, promotable advantages to patients and payers.”
Merck reiterated its full-year adjusted earnings per share guidance of $3.45 to $3.55. The company expects to take restructuring charges totaling $900 million to $1.1 billion in its third quarter.
Merck’s shares are up 2.7% in premarket trading this morning, at $48.95 in a 52-week range of $40.02 to $50.16. The Thomson/First Call consensus price target for the shares is around $51.80.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
